Kartesia has provided Enterprise Investors portfolio company Nu-Med with a €32m refinancing package.
The package will go towards refinancing all existing financial debt and supporting Nu-Med in its growth plan.
This is the first deal for Kartesia in Poland. Capital for the deal will be drawn from Kartesia Credit Opportunities (KCO) IV and V funds. The firm's fourth fund closed on €870m in October 2017 and offers debt and equity packages of €10-60m to European small and mid-cap companies. KCO V was registered in March 2019 and, according to Unquote Data, is still fundraising.
Enterprise put the asset up for sale, with PwC advising, but did not achieve a sale, according to Unquote sister publication Mergermarket.
Headquartered in Elblag, Poland, Nu-Med is a private operator of four oncology centres in Poland and was founded in 2013.
Kartesia – Giuseppe Mirante (head of DACH credit opportunities).
Nu-Med Group – Paweł Paczkowski (CEO).
Nutrisens management team, led by CEO Georges Devesa, retains a significant stake in the company
Intention to list comes four years after the GP acquired the company via its fourth fund
Online optician has previously received VC funding from investors including Grazia Equity and Goldman Sachs
Platform will enable smaller investors to put their secondaries stakes up for sale